As shown in Fig. 4, SLC16A3 expression was significantly upregulated in liver cancer specimens compared to non-tumor liver specimens in both GSE25097 (p < 0.001; Fig. 4A) and GSE36376 (p < 0.001; Fig. 4D), while POLOCE (GSE25097: p < 0.001; Fig. 4B, GSE36376: p < 0.001; Fig. 4E) and ZBTB16 (GSE25097: p < 0.001; Fig. 4C, GSE36376p = 0.001; Fig. 4F) expression levels was significantly lower in liver cancer specimens compared to non-tumor specimens. This evidence concerns the gene SLC16A3 and liver cancer.